Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 137Parkinson Disease 4, Autosomal Dominant Lewy Body 125Melanoma 95Neoplasms 75Squamous Cell Carcinoma of Head and Neck 65Colorectal Neoplasms 42Triple Negative Breast Neoplasms 38Carcinoma, Renal Cell 37Lung Neoplasms 36Stomach Neoplasms 35Head and Neck Neoplasms 34Breast Neoplasms 34Urinary Bladder Neoplasms 32Neoplasm Metastasis 32Carcinoma, Hepatocellular 32Pancreatic Neoplasms 30Ovarian Neoplasms 29Carcinoma, Transitional Cell 25Endometrial Neoplasms 19Recurrence 16Sarcoma 15Esophageal Neoplasms 15Carcinoma 15Uterine Cervical Neoplasms 14Prostatic Neoplasms 14Small Cell Lung Carcinoma 13Lymphoma 13Fallopian Tube Neoplasms 13Carcinoma, Squamous Cell 13Lymphoma, Non-Hodgkin 12

Interventions

Bevacizumab 3Radiosurgery 2Irinotecan 2pembrolizumab 1Vorinostat 1Valproic Acid 1Thalidomide 1Temozolomide 1Surveys and Questionnaires 1Sorafenib 1Sildenafil Citrate 1Pliability 1Nivolumab 1Morphine 1Methadone 1Exercise 1Equipment and Supplies 1Eating 1Carboplatin 1Amifampridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neurologic Manifestations × pembrolizumab × Clear all
NCT02313272 2023-10-23

Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
32 enrolled 12 charts
CNS

Glioma, Neoplasms, Neurologic Manifestations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡